Home » Opsona Therapeutics Achieves Orphan Designation for Myelodysplastic Syndrome with OPN-305
Opsona Therapeutics Achieves Orphan Designation for Myelodysplastic Syndrome with OPN-305
Dublin-based Opsona Therapeutics has received orphan drug designation from the US FDA for myelodysplastic syndromes.
OPN-305 is a novel proprietary humanized IgG4 monoclonal antibody against Toll-Like Receptor 2, a key target within the innate immune system.
A study in patients with lower-risk MDS who have failed hypomethylating agents is ongoing in collaboration with MD Anderson Cancer Center in Houston.
Upcoming Events
-
07May
-
14May
-
30May